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ABSTRACT 
%DFNJURXQG+XQWLQJWRQ¶VGLVHDVHFDQSUHVHQWDWDOPRVWDQ\DJHEXWWUDGLWLRQDOO\
WKRVHZLWKDQRQVHW\HDUVDUHGHVFULEHGDVKDYLQJMXYHQLOHRQVHW+XQWLQJWRQ¶V
disease (JOHD). They are more likely to have bradykinesia and dystonia earlier in 
the coursHRIWKHGLVHDVH7KH7RWDO0RWRU6FRUHRIWKH8QLILHG+XQWLQJWRQ¶V
Disease Rating Scale (UHDRS-TMS) is often used as the principal outcome 
measure in clinical trials.  
Objective: To identify a motor scale more suitable for JOHD patients  
Methods: A working group reviewed the UHDRS-TMS and modified it by adding four 
further assessment items.  Rasch analysis was used to study the performance of the 
modified scale in 95 patients with a mean age of 19.4 (SD 6.6) years.  
Results: The initial analysis showed a significant overall misfit to the Rasch model 
and a number of individual items displayed poor measurement properties: all items 
relating to chorea displayed significant misfit due to under-discrimination. 
Additionally, a number of items displayed disordered response category thresholds, 
and a large amount of dependency was present within the item set (96 out of 741 
pairwise differences = 13%). An iterative process of scale re-structuring and 
evaluation was then undertaken, with a view to eliminating the largest sources of 
misfit and generating a set of items that would conform to Rasch model 
expectations.  
Conclusion: This post-hoc scale restructuring appears to provide a valid motor score 
that is psychometrically robust in a JOHD population. This scale restructuring offers 
a pragmatic solution to measuring motor function in a JOHD population, and it could 
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provide the basis for the further iterative development of a more useful clinical rating 
scale for patients with JOHD. 
 
Key Words: Rasch, JXYHQLOH2QVHW+XQWLQJWRQ¶V'LVHDVH7RWDO0RWRU6FRUH 
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INTRODUCTION  
+XQWLQJWRQ¶VGLVHDVH+'LVDSURJUHVVLYHQHXURGHJHQHUDWLYHGLVRUGHULQKHULWHGDV
an autosomal dominant condition. It is characterised by a movement disorder, 
selective cognitive impairment and disturbance of affect. The disease results from an 
expansion of a CAG repeated sequence in the first exon of the HTT gene.  A CAG 
repeat length of 36 -39 is associated with reduced penetrance whereas 40 or more is 
considered unequivocally abnormal. Onset may occur at almost any age but it is 
typically in midlife.  [1][2][3][4] There is a negative correlation between age of onset 
and CAG repeat length, consequently those with JOHD often have a higher CAG 
repeat length. 
The term juvenile onset HD (JOHD) is used to describe a patient having an age of 
RQVHWRI\HDUVLQZHOOGHYHORSHGFRXQWULHVWKLVUHSUHVHQWs approximately 5% of 
cases [5]. This is not a distinct subcategory but remains a distinction because the 
phenotype is more likely to include bradykinesia and dystonia at an earlier stage of 
the illness, and little in the way of chorea. Clear problems arise with this definition 
because of the cut-off age of 20 years: firstly, it is arbitrary; a patient with onset at 18 
years may not be significantly different from one with an age of onset of 22 years; 
secondly, a patient with onset under 10 years may have very different needs from a 
patient with onset as a late teenager; thirdly, a patient now aged 30 years could still 
KDYHKDGDJHRIRQVHW\HDUV 
Currently, there is no treatment to alter the natural history of the disease but 
WUHDWPHQWWULDOVDUHXQGHUZD\IRUDGXOWRQVHW+XQWLQJWRQ¶VGLVHDVH[6] using 
standardised rating scales as outcome measures such as the Total Motor Score of 
WKH8QLILHG+XQWLQJWRQ¶V'LVHDVH5DWLQJ6FDOH8+'56 [7].  
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However, to ensure that the impact of any interventions being studied in clinical trials 
is assessed accurately, it is vital that the outcome measures adequately represent 
the constructs that the interventions are meant to treat or modify. 
The UHDRS was developed and psychometrically validated using traditional 
approaches. However, modern psychometric assessment methodologies such as 
item response theory (IRT) [8] [9] [10] [11] and Rasch Measurement Theory (RMT) 
[12] offer various advantages over classical approaches, and can also reveal 
potential restrictions that may be present within these existing measures [13] [14]. 
Where traits cannot be measured directly, these are known as latent traits (e.g. 
depression, or quality of life). Latent traits are measured by indirect means, which is 
usually through multi-item scales. Rasch Measurement Theory provides a way to 
assess multi-item latent scales (i.e. Patient or Clinician-Reported Outcome 
Measures), to ensure that it is valid to add the individual  items together to form an 
overall total score. The Rasch model is a unidimensional measurement model that 
satisfies the assumptions of fundamental measurement [15] [16], meaning that it 
provides a measurement template that scales can be tested against. The 
assumption that all items contribute independently to the total score is formally 
tested against the Rasch model, and any measurement anomalies within the item 
set are highlighted. The application of Rasch Measurement Theory provides a 
unified framework for several aspects of internal construct validity to be assessed. 
This includes the assessment of scale unidimensionality (whether all items are 
contributing to the same underlying construct), response category functioning 
(whether item response categories are working as they were intended to be used), 
response dependence (whether the response to any item has a direct implication to 
the response to any other item), scale targeting (relative distribution of item and 
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person locations), and item bias (whether an item is working in the same way for 
specific groups. e.g. males and females). When rating scale data conform to the 
Rasch model, the ordinal raw score can be transformed into a linear, interval scale, 
thus validating the use of parametric statistical procedures, although it should be 
noted that the raw score will remain ordinal. 
The purpose of this study was to use a Rasch analytic framework to investigate the 
psychometric properties of a modified UHDRS motor scale on patients with JOHD. 
The UHDRS has already been assessed within an item response theory (IRT) 
framework [17], but the majority of subjects within that study had adult onset HD. 
Additionally, RMT offers a different approach to IRT. Whereas the IRT approach 
seeks to explain the variance in the data by adjusting the model to fit the data, in the 
RMT approach the model remains fixed, seeking to obtain invariant measurement by 
ensuring that items meet the requirements of the fixed model [18,19]  
Furthermore, given the motor phenotype of JOHD, four items that quantified motor 
features common in JOHD were added to the UHDRS-TMS with a view to seeing if 
this helped the performance of the rating scale within a JOHD sample. 
 
 
METHODS 
$ZRUNLQJJURXSRIWKH(XURSHDQ+XQWLQJWRQ¶V'LVHDVH1HWZRUNPHWWRFRQVLGHUWKH
issue of assessing JOHD patients for intervention studies. Based on the opinion of 
an expert group,  a  strategic decision was made to retain the structure of the Total 
Motor Score scale, but an additional four items were added: 1) an overall chorea 
score:  the current motor scale is heavily weighted towards chorea with an 
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assessment of seven areas (face, buccal, oral, lingual, trunk, right and left upper 
extremities) and as this clinical sign is less prominent in JOHD, an overall chorea 
may give a better assessment; 2) a repetitive hand-tapping task which quantifies 
bradykinesia; 3) a task timing how long it would take to drink 120 ml of water as 
another measure of capturing slowing of movements; and 4) a maximal tremor score 
because this has been suggested as a common clinical sign in JOHD. The modified 
scale has 39 items, each with five response categories, where a higher score 
represents a higher level of impairment; the additional items and responses are 
listed in Table 1. 
This was a sub-VWXG\RIWKH(XURSHDQ+XQWLQJWRQ¶V'LVHDVH1HWZRUN5(*,675<
project  [20]: the ethical approval for REGISTRY included sub-studies.  More 
information on the study can be found at http://www.euro-hd.net/html/registry  [21].  
Data from this extended JOHD motor assessment rating scale was collected from 
patients in Europe, the United States and Australia and submitted in paper form to 
the EuropHDQ+XQWLQJWRQ¶V'LVHDVH1HWZRUN5(*,675<VLWHDW8OPDQGHQWHUHG
onto an Excel spread sheet. 
Participants 
Data was collected from 27 sites using multiple raters. Initially, there were 111 
participants (58 females, 53 males) with a mean age of 21.3 years (SD 8.05, Range 
6-40). Although it is possible for a person to develop HD as a late teenager and now 
be aged 40, the object of this study was to focus on the performance of the rating 
scale among younger patients; therefore, the analysis was restricted to those 
patients \HDUV at the time of the study. This reduced the sample size to n=95. 
Rasch Analysis of the data 
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The JOHD motor scale data was analysed using RUMM2030 software to investigate 
whether the pattern of item responses observed in the data matched the 
expectations of the Rasch measurement model [22]. The following fundamental 
aspects of the scale were assessed using this approach:  overall fit to the model, 
adequacy of the response categories, individual item and person fit, local 
dependency, unidimensionality, differential item functioning (DIF), targeting of the 
scale and person separation reliability index (PSI). All of these elements have been 
previously described elsewhere [23] [24] [25]. Briefly, the data is compared to the fit 
assumptions of the Rasch model, so the tests-of-fit should be non-significant for the 
model assumptions to be satisfied. Individual items should demonstrate chi-square 
and ANOVA fit statistics >0.05 (Bonferroni adjusted), and the same ranges are 
applicable for any DIF tests. A residual correlation (Q3) value of 0.2 was used to 
indicate dependency. This is slightly more lenient than the value of 0.2 above the 
average correlation that is currently recommended [25], but it was felt that this was a 
reasonable compromise, given the low sample size involved. A series of t-tests were 
used to assess unidimensionality [26], where evidence of unidimensionality is 
apparent when the lower bound 95% CI percentage of significantly different t-tests is 
< 5%. 
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RESULTS 
The 95 patients in this study had a male:female ratio of 45:50. The mean age was 
19.4 years (SD 6.6 years). The age distribution was 6 ± 30 years:  13 were aged 6-
10 years; 34 were aged 11-20 years and 48 were ages 21- 30 years.  The mean 
CAG repeat length was 67.6 (SD 15.6). The median CAG repeat length was 63 
(inter-quartile range 56-77) with a range of 46-117. 
Analysis 
The initial analysis showed a significant overall misfit to the Rasch model (see Table 
2, Analysis 1), and a number of individual items displayed poor measurement 
properties.  At this point, the key observation was that all items relating to chorea 
(both the original 7-area assessment and the overall chorea score) displayed 
significant misfit due to under-discrimination. This suggests that the chorea items are 
not usefully contributing to the total score of the item set due to a lack of 
discrimination within this patient group. An example of this under-discrimination is 
presented in Figure 1. Additionally, a number of items displayed disordered response 
category thresholds (see Figure 2), and a large amount of dependency was present 
within the item set (96 out of 741 pairwise differences = 13%). It was noted that the 
majority of the dependency was clustering into groups of items that were related to 
the same concept; for example, dystonia in the right and left upper limb.  
An iterative process of scale re-structuring and evaluation was then undertaken, with 
a view to eliminating the largest sources of misfit and generating a set of items that 
would conform to Rasch model expectations. The summary results of each analysis 
stage are presented in Table 2. 
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Analysis 2 Restructuring of the data to reduce dependency. 
The first stage of data reconstruction was carried out in order to reduce the impact of 
item dependency. This was done by creating a number of composite items, which 
considered the maximum level of impairment shown within a dependent cluster of 
items. This approach conserves the informative clinical information, whilst taking 
account of the psychometric impact of inter-item dependency. Practically, this meant 
WKDWWKHµULJKW¶DQGµOHIW¶HOHPHQWVRIWKHLWHPVSURQDWHVXSLQDWHKDQGVULJLGLW\RI
arms, finger taps, bradykinesia, hand-tapping, tremor upper extremity and tremor 
lower extremity were combined into single items, with the highest value of the right 
and left elements selected for the composite item. Similarly, the assessment of 
maximal dystonia was reduced from five elements down to three, with the retention 
RIµWUXQN¶DVDVLQJOHLWHPEXWFRPELQLQJ WKHµULJKW¶DQGµOHIW¶HOHPHQWVUHODWLQJWRWKH
upper and lower extremity. Additionally, the assessments of eye movements were 
UHVWUXFWXUHGWRFRPELQHWKHµKRUL]RQWDO¶DQGµYHUWLFDO¶HOHPHQWVRIWKHRFXODUSXUVXLW
saccade initiation, and saccade velocity items. 
None of the chorea items appeared to discriminate across the level of motor function 
in the initial analysis, and all elements clustered in terms of the evidence of 
dependency. To investigate whether the under-discrimination remained present with 
a single maximal chorea value, all of the original 7 assessments of chorea were 
combined into a single maximal chorea item, selecting the highest observed value 
across all elements. The global chorea item was also retained individually at this 
stage. 
These amendments resulted in the reduction of the item set from 39 to 22 items, 
each with five available response categories. These amendments are represented 
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DVµUHVWUXFWXUHUXQ¶LQ7DEOH, and the fit statistics are presented as Analysis 2 in 
Table 2. 
 
Analysis 3: Further restructuring of the data to remove dependency. 
A degree of response dependency was still present at this point, leading to further 
restructuring. This included the combination of all elements of saccade initiation and 
velocity into a single composite item, all elements of dystonia into a single composite 
item, and all elements of tremor into a single composite item.  These further 
amendments resulted in the reduction of the item set to 18 items, each with five 
available response categories. These amendments are represented aVµUHVWUXFWXUH
UXQ¶LQ7DEOe 3, and the fit statistics are presented as Analysis 3 in Table 2. 
 
Analysis 4: Removal of chorea due to under-discrimination 
At this stage, both the newly created chorea composite item and the original global 
chorea item continued to display a large degree of misfit due to under-discrimination. 
Both of these items were duly removed from the item set, therefore reducing the 
scale to 16 items. The fit statistics at this stage are presented as Analysis 4 in Table 
2. 
 
Analysis 5: Collapsing of response categories due to disordered response. 
After accounting for the majority of the response dependencies and removing the 
clear anomalies of the chorea items, six items were still displaying disordered 
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response categories, indicating that they did not seem to be functioning in the 
intended manner. With guidance from the patterns of disorder and expert input from 
an experienced HD clinician, the response categories of these six items were 
collapsed. In the case of the items relating to the retropulsion pull test, maximal 
dystonia and Luria tri-step score, the response categories were reduced from five to 
four. In the case of the items relating to tongue protrusion, maximal rigidity of arms 
and bradykinesia of drinking, the response categories were reduced from five to 
three. Although this is presented as a single analysis stage, all rescoring was carried 
out iteratively. The rescoring structure is presented in Table 4, with the pre and post-
rescoring response category threshold plots presented in Figure 3. The fit statistics 
at this stage are presented as Analysis 5 in Table 2. 
 
Analysis 6 & 7 ± removal of tremor and dysarthria items 
)ROORZLQJWKHUHVFRUHWKHµPD[WUHPRU¶FRPSRVLWHLWHPZDVVWLOOGLVSOD\LQJDPLVILW
due to an under-discrimination (similar to the chorea items). Additionally, the 
µG\VDUWKULD¶LWHPZDVDOVRGLVSOD\LQJDPLVILWDOWKRXJKWKLVLWHPZDVLQGLFDWLQJDQ
over-discriminating response pattern in addition to displaying a lower-level 
dependency across a number of items, which seemed to be adversely influencing 
WKHGLPHQVLRQDOLW\RIWKHLWHPVHW7KHµPD[WUHPRU¶DQGµG\VDUWKULD¶LWHPVZHUH
iteratively removed from the item set, and the fit statistics are presented as Analysis 
6 and 7 respectively, in Table 2. 
Following the removal of these two items, the overall fit was good (chi-square 
p=0.297), individual item fit was good, dimensionality was acceptable (7/95 = 7.37% 
[95% CI = 3-11.8%]), all response categories were ordered, and there was no DIF by 
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gender, handedness, or the version of the scale that was administered (adult or 
JOHD-specific). The relative person-item distribution (targeting) plot also indicated 
that the remaining item set still captured the full range of impairment, meaning that 
the scale reliability statistics remained high (see Figure 4). However, some 
dependency remained apparent between the two items measuring balance 
(retropulsion pull and tandem walk) (0.316), and a lower-level dependency between 
WKHµPD[ULJLGLW\DUPV¶DQGµPD[G\VWRQLDLWHPV¶ 
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Discussion 
To our knowledge, this is the first attempt to assess the motor scale of the UHDRS 
on a population of people with JOHD. The motor scale revealed areas of significant 
dependency between clusters of items relating to different elements of common 
concepts, including a consistent dependency between the right and left side of 
impairments to motor function.  A post-hoc correction was applied to account for the 
apparent dependency, which also went some way to alleviating the apparent lack of 
unidimensionality within the item set. At a practical level, this reduces the amount of 
items that are summed to form the total score, but the key clinical information 
relating to the location of impairment is retained. Given the nature of the observed 
dependencies within the item set, it is reasonable to expect a similar finding to be 
observed within the UHDRS motor scale when applied to patients with adult onset 
HD.  
Additionally, it appears as though the five-category response options are not working 
as intended across all items. This can mean that respondents are not differentiating 
between certain responses, and therefore the response choice between these 
categories becomes arbitrary. This may be the case where too many response 
options are presented, or if response category labelling is unclear, inconsistent, or 
GLIILFXOWWRTXDQWLI\)RUH[DPSOHWKLVDSSHDUHGWREHWKHFDVHZLWKWKHµWRQJXH
SURWUXVLRQ¶LWHPZKHUHUHVSRQGHQWVDSSHDUHGWRKDYHGLIILFXOW\GLVWLQJXLVKLQJ
EHWZHHQUHVSRQVHFDWHJRULHVODEHOOHGVXFKDVµFDQQRWIXOO\SURWUXGHWRQJXH¶DQG
µFDQQRWSURWUXGHWRQJXHEH\RQGOLSV¶,QWKLVFDVHWKHDQDO\VLVKDVKLJKOLJKWHGDQ
issue which is made clearer when put into context. As these two response categories 
are not mutually exclusive, it is perhaps not surprising that respondents are not 
clearly differentiating between the available response options. Again, a post-hoc 
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adjustment was made to the scale by collapsing some of the response categories of 
the items displaying disordered thresholds. Although this improved scale fit, it should 
be noted that the actual response options (as presented) have not changed. The 
process of collapsing merely treats certain response options as equivalent; the 
practical application of this is described below. 
Furthermore, it was recognised from the outset of the original scale development, 
that the motor scale was heavily weighted towards chorea, and for this reason the 
global chorea score was introduced.  Within the reference frame of the JOHD 
sample, it was shown that none of the items relating to chorea were usefully 
discriminating across different levels of the trait, including the new global chorea 
score. It is to be expected that a worsening chorea score would be associated with a 
worsening overall motor score, but this was not found to be the case in the JOHD 
sample. This has significant implications for clinical trials because the UHDRS-TMS 
is heavily weighted towards chorea. The objective of current research is to provide 
disease modifying treatments.  The recent work by Schobel et al to modify the 
principal outcome measure is helpful but still uses theUHDRS-TMS in the formula 
[27]  in chorea.   
Although the amended (collapsed) bradykinesia drinking item appeared to work well 
within the final item set, the feedback from scale users has raised concerns 
regarding this item. These concerns relate to the practical aspect associated with 
drinking 120ml of water, as this may create a potential choking hazard. This item 
should therefore be considered carefully within any future scale development. 
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Of the remaining new items: the assessment of tremor did not prove useful because 
it was removed at the analysis stage; however the bradykinesia hand tapping 
assessment was retained. 
The major limitation of this study was the sample size that was available for analysis 
(n=95). A sub-analysis to investigate the effect of CAG repeat length on the 
performance of the scale could not be undertaken.  However, given the relative rarity 
of JOHD, it took an enormous amount of time and resource to collect a sample of 
this apparently modest size, so this sample size should be considered in context. It is 
acknowledged that this small sample size may result in more instability surrounding 
the analysis results. However, the magnitude of the results and the replication of the 
key findings suggest a larger sample would deliver largely equivalent results. A 
further limitation is that age of onset was not collected systematically as data were 
collected separately from the main REGISTRY data, so we were not able to stratify 
the results into WKRVHZLWKRQVHW\HDUVIURPWKRVHZLWKRQVHWLQWKHLUODWHWHHQV
:HWULHGWRPLWLJDWHWKLVOLPLWDWLRQE\UHVWULFWLQJWKHVWXG\WRWKRVH years of age. 
 
Conclusion 
This study was designed to assess the use of a modified motor scale in JOHD.  The 
modifications from the adult-oriented UHDRS motor scale were modest, as it was 
thought that making additional assessments would result in the scale being more 
focused for the JOHD population. This study has revealed some significant 
implications for assessing future treatments in young people with HD.  The analysis 
suggests that it is not valid to sum the 39 items (35 original, and 4 newly added) of 
the UHDRS-JOHD motor scale into a single total score. 
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On the basis of this result the HD research community could consider the following 
options: (1) Continue using the UHDRS-TMS and accept its limitations; (2) Retain 
the UHDRS-TMS, but additionally include the new hand tapping task; (3) Retain the 
UHDRS-TMS plus the hand tapping task so that it does not look any different to the 
practising clinician undertaking an intervention study. However, it will be necessary 
to pre-specify that any outcomes will be based on post-hoc changes to the scale, as 
described in this study; (4) Redesign the JOHD motor rating scale from the ground 
up, using qualitative and quantitative methods to iteratively develop a motor rating 
scale which is clinically meaningful. 
Ideally a rating scale should focus on functional assessments rather than an 
amalgam of clinical signs. Although option 4 would perhaps present the best 
solution, in the short term we would recommend option 3 because it has the practical 
merit of being easily adopted without significant further work. However, option 4 
should be considered as a future direction in which to take this informative work, 
which is presented as part of an iterative development process. 
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Table 1. Summary of the four additional items used in this study 
Chorea Global 
0 = absent 
1 = slight/intermittent 
 2 = mild/common or moderate/intermittent 
 3 = moderate/common 
 4 = marked/prolonged 
Bradykinesia ± hand tapping 
0 = > 100 in 30 seconds 
 1 = 80-100 in 30 seconds 
 2 = 60-79 in 30 seconds 
 3 = 40-59 in 30 seconds 
 4 = < 40 in 30 second 
Bradykinesia ± drinking 
0= <5 seconds to drink 120ml of water 
 1 = 5-7 seconds to drink 120ml of water 
 2 = >7-11 seconds to drink 120ml of water 
 3 = >11 to 18 seconds to drink 120ml of water 
 4 = >18 seconds to drink 120ml of water 
Total time to drink 120 ml of water 
Maximal tremor 
0 = absent 
 1 = slight/intermittent 
 2 = mild/common 
 3 = moderate/common 
 4 = marked and severe 
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Table 2 Ȃ Analysis stage summary fit details 
 
Analysis 
Number 
Description 
no. of 
items 
n 
Item Fit 
Residual 
Person Fit 
Residual 
Chi Square 
Interaction 
PSI Alpha 
Unidimensionality 
% significant t-
tests (lower 
bound 95%CI) 
no. of 
pairwise 
dependencies 
>0.2 Mean SD Mean SD Value df P 
1 Initial analysis 39 95 -0.18 1.51 -0.2 1.55 261.7 78 >0.0005 0.95 0.95 35.8% (31.4%) 96/741 (13%) 
2 
dependency 
reduction run 1 22 95 0.03 1.84 -0.06 1.19 184.8 44 >0.0005 0.94 0.94 21.05% (16.7%) 19/231 (8%)  
3 
dependency 
reduction run 2 18 95 0.02 2.04 -0.06 1.19 186.1 36 >0.0005 0.93 0.93 18.95% (14.6%) 11/153 (7%) 
4 
remove both chorea 
items 16 95 0.24 1.74 0.06 1.05 86.84 32 >0.0005 0.94 0.94 10.53% (6.1%) 6/120 (5%) 
5 rescore items 16 95 0.04 1.58 -0.01 1.02 64.24 32 0.0006 0.94 0.94 10.53% (6.1%) 5/120 (4%) 
6 
remove max tremor 
item 15 95 0.06 1.27 -0.06 0.9 38.59 30 0.135 0.94 0.94 9.47% (5.1%) 2/105 (2%) 
7 
remove dysarthria 
item 14 95 0.08 0.99 -0.06 0.84 31.45 28 0.297 0.94 0.94 7.37% (3.0%) 2/91 (2%) 
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Table 3. Restructure framework 
 
Item 
number 
Descriptor 
Item number 
under 
restructure run: 
New item 
1 2 
1 ocular pursuit horizontal 
1 1 max ocular pursuit 
2 ocular pursuit vertical 
3 saccade initiation horizontal 
2 
2 max saccade 
4 saccade initiation vertical 
5 saccade velocity horizontal 
3 
6 saccade velocity vertical 
7 dysarthria 4 3 dysarthria 
8 tongue protrusion 5 4 tongue protrusion 
9 finger taps right 
6 5 max finger taps 
10 finger taps left 
11 pronate/supinate hands right 
7 6 
max 
pronate/supinate 
hands 12 pronate/supinate hands left 
13 Luria tri step test 8 7 Luria 
14 rigidity-arms right 
9 8 max rigidity arms 
15 rigidity-arms left 
16 bradykinesia - body 10 9 bradykinesia - body 
17 maximal dystonia trunk 11 
10 max dystonia 
18 maximal dystonia RUE 
12 
19 maximal dystonia LUE 
20 maximal dystonia RLE 
13 
21 maximal dystonia LLE 
22 maximal chorea face 
14 11 max chorea 
23 maximal chorea BOL 
24 maximal chorea trunk 
25 maximal chorea RUE 
26 maximal chorea LUE 
27 maximal chorea RLE 
28 maximal chorea LLE 
29 gait 15 12 gait 
30 tandem walking 16 13 tandem walking 
31 retropulsion pull test 17 14 retropulsion pull test 
32 chorea ± global 18 15 chorea - global 
33 
bradykinesia ± hand tapping 
right 
19 16 
max bradykinesia ± 
hand tapping 
34 
bradykinesia ± hand tapping 
left 
35 bradykinesia - drinking 
20 17 
bradykinesia - 
drinking 
36 maximal tremor RUE 
21 
18 max tremor 
37 maximal tremor LUE 
38 maximal tremor RLE 
22 
39 maximal tremor LLE 
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Table 4. Rescoring structure 
    
Original response category 
Item Statement 
Max 
Score 
Rescored 1 2 3 4 5 
1 max ocular pursuit 4   0 1 2 3 4 
2 max saccade 4   0 1 2 3 4 
3 dysarthria 4   0 1 2 3 4 
4 tongue protrusion 2 Y 0 1 1 2 2 
5 max finger taps 4   0 1 2 3 4 
6 max pronate/supinate hands 4   0 1 2 3 4 
7 Luria tri step test 3 Y 0 1 1 2 3 
8 max rigidity arms 2 Y 0 1 1 2 2 
9 bradykinesia - body 4   0 1 2 3 4 
10 max dystonia 3 Y 0 1 1 2 3 
12 gait 4   0 1 2 3 4 
13 tandem walking 4   0 1 2 3 4 
14 retropulsion pull test 3 Y 0 1 2 3 3 
16 
max bradykinesia ± hand 
tapping 
4   0 1 2 3 4 
17 bradykinesia - drinking 2 Y 0 1 1 2 2 
18 max tremor 4   0 1 2 3 4 
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Figure 1. Item Characteristic Curve of the under-discriminating Chorea item 
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Figure 2. Example of items with ordered thresholds (Max. Finger Taps Ȃ 
upper plot) and disordered thresholds (Bradykinesia Drinking Ȃ lower 
plot) 
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Figure 3. Item threshold map pre and post-rescoring 
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Figure 4. Relative person-item threshold distribution of final 14 items 
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Legends to Figures 
 
Figure 1 
The grey line represents the expected response curve, and the black dots represent 
WKHREVHUYHGGDWD7KHµIODW¶QDWXUHRIWKHcurve suggests that respondents are 
obtaining an approximately equal value on the item, regardless of their underlying 
level of motor function (as represented by the x-axis), and is therefore not 
discriminating across the level of motor function.  
Figure 2  
Each curve represents the inferred probability distribution of persons responding in a 
particular response category, given their underlying level of motor function. Each 
response category should emerge at some point as the most likely response on the 
underlying scale. In turn, all response category thresholds should therefore be 
ordered (see upper plot). Where response categories do not function as intended, 
response category thresholds become disordered (see lower plot). 
Figure 3 
Plot shows the relative location of all response category thresholds across all items. 
Where no plot is shown for an item, the thresholds were disordered.  
Figure 4 
Plot shows the relative distribution of logit locations of all item thresholds (below x-
axis) and persons (above x-axis). These distributions should align where a scale is 
well-targeted to the population being measured. 
 
